Adamis Anthony P, Berman Adrienne J
Jerini Ophthalmic, Time & Life Building, 111 West 50th Street, 7th Floor, Gilman 7-422A, New York, NY 10020, USA.
Semin Immunopathol. 2008 Apr;30(2):65-84. doi: 10.1007/s00281-008-0111-x. Epub 2008 Mar 14.
There is an accumulating body of evidence that immunological mechanisms play a prominent role in the pathogenesis of diabetic retinopathy (DR), which is characterized by many features typical of inflammation. The upregulation of cytokines and other inflammatory mediators leading to persistent low-grade inflammation and an influx of leukocytes, is believed to contribute actively to DR-associated damage to the retinal vasculature and retinal neovascularization. This review will describe preclinical and clinical studies that document an inflammatory basis for DR and that support the use of nonsteroidal anti-inflammatory drugs, corticosteroids, and anti-vascular endothelial growth factor agents in its treatment. In addition, emerging therapeutic approaches based on ongoing investigations will be discussed, including those involving blockade of angiotensin receptors and other molecular targets such as tumor necrosis factor-alpha.
越来越多的证据表明,免疫机制在糖尿病视网膜病变(DR)的发病机制中起着重要作用,DR具有许多典型的炎症特征。细胞因子和其他炎症介质的上调导致持续的低度炎症以及白细胞的流入,被认为是DR相关的视网膜血管损伤和视网膜新生血管形成的重要原因。本综述将描述临床前和临床研究,这些研究证明了DR的炎症基础,并支持在其治疗中使用非甾体抗炎药、皮质类固醇和抗血管内皮生长因子药物。此外,还将讨论基于正在进行的研究的新兴治疗方法,包括那些涉及阻断血管紧张素受体和其他分子靶点(如肿瘤坏死因子-α)的方法。